BeiGene Ltd Stock News

The U.S. Food and Drug Administration has approved BeiGene's drug to treat a type of esophageal cancer in patients who have previously received chemotherapy.

The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain patients with a type of blood cancer, the health regulator sa

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the qua

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

DOYU, STLA, BGNE, LEGH and WTS have been added to the Zacks Rank #1 (Strong Buy) List on December 22, 2023.

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Co

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it wil

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the present

BeiGene said on Tuesday it has entered into an agreement with biotech company Ensem Therapeutics to acquire a global license for a cancer therapy that is ready to enter early-stage trial.

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Co